Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery doi: 10.1158/2159-8290. PMID: 30787016 PMCID: PMC6497554
The BAM files for WES and RNA seq used in the article "Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases." on cancer Discovery 2019. PMID: 30787016 PMCID: PMC6497554. Authors : Grant M Fischer, ..., Michael A Davies.
- 199 samples
- DAC: EGAC00001001216
- Technologies: Illumina HiSeq 2000, Illumina MiSeq
This is the data access policy which aims to ensure the data applicant agrees to the terms before the access approval.
DATA ACCESS AGREEMENT This Data Access Agreement (“Agreement”), effective as of the ____ day of _________________, 20__ (“Effective Date”), is by and between The University of Texas M. D. Anderson Cancer Center, an institution of The University of Texas System and an agency of the State of Texas, with an address at 1515 Holcombe Boulevard, Houston, Texas 77030 (“Provider”), and _____________ (“Recipient”) on behalf of its investigator _____________ (“Recipient Investigator”) (collectively, the “Parties”; each, a “Party”). RECITALS Provider maintains the following de-identified data in the European Genome-phenome Archive (EGA) managed by the European Bioinformatics Institute __[description of data]__ (“Data”), and Provider is willing to allow Recipient to access such Data from the EGA for the internal noncommercial research purposes of ___[research purpose]___ (“Purpose”), pursuant to the terms of this Agreement. In consideration of the mutual promises and covenants herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 1. The Data will be used solely for the Research by Recipient Investigator and personnel under his immediate supervision at Recipient, and may not be transferred to any other investigator or to any third party without prior written permission from Provider. The Material may not be used for any purpose other than the Research, including without limitation for any commercial purpose or for research in human subjects (including, without limitation, in diagnostic testing). 2. Neither Recipient nor Recipient Investigator shall disclose Data to any person or party other than the Recipient Investigator hereunder without Provider’s prior written consent. 3. The Data will be used in compliance with all applicable laws, regulations, and guidelines applicable to the Data, including without limitation any applicable export controls. 4. In any publication resulting from use of the Data, Recipient and Recipient Investigator shall acknowledge ______________ (“Provider Investigator”) and Provider as the provider of the Data. 5. This Agreement shall be effective as of the Effective Date and shall remain effective until completion of the Research. Either Party may terminate this Agreement with or without cause upon thirty (30) days’ written notice to the other Party. Upon expiration or termination of this Agreement for any reason, Recipient shall destroy all Data received pursuant to this Agreement. 6. Any notice permitted or required as provided for herein shall be in writing and to the contact and address as noted below or as may be provided by either party to the other in writing from time to time. Notice to Provider shall be to: Chief Legal Officer The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd., Unit 1674 Houston, Texas 77030 Phone: 713-745-6633; Facsimile: 713-745-6029 With a copy to: The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd., Unit 1676 Office of Research Administration Attn: AVP, Research Administration Houston, TX 77030 Phone: 713-792-3672; Facsimile: 713-792-7455 Notice to Recipient shall be to: __________________________ __________________________ __________________________ __________________________ __________________________ 7. In the event Protected Health Information (“PHI”), as defined by the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended, is inadvertently created, accessed by, and/or disclosed to Recipient in connection with this Agreement, Recipient will immediately notify the Provider and will return to Provider or destroy such PHI, in accordance with the Provider’s instructions. Pending return or destruction of any PHI, Recipient shall maintain the confidentiality of all Data (including the PHI) and use appropriate safeguards to prevent access to, use, or disclosure of Data (including the PHI). 8. PROVIDER MAKES NO REPRESENTATION OR WARRANTY CONCERNING THE MATERIAL, INCLUDING WITHOUT LIMITATION, WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. 9. Recipient Investigator and Recipient accept all liability for any use of the Data and for any loss, claim, or damage which may arise from or in connection with this Agreement or the use, handling or storage of the Data and in no event shall Provider or Provider Investigator be liable for any such use, loss, claim or damage. 10. This Agreement is via EGA mechanism. [Insert Recipient Name Here] THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER By: By: Name: ____________ ______ Name: ____________ Title: _____________ ______ Title: ____________ ______ Date: Date: Read and Understood: Read and Understood: Recipient Scientist: Provider Scientist: Name: ____________ ______ Name: ____________ Title: _____________ ______ Title: ____________ ______ Date: Date:
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
|Study ID||Study Title||Study Type|